Your browser doesn't support javascript.
loading
Development of Highly Optimized Antibody-Drug Conjugates against CD33 and CD123 for Acute Myeloid Leukemia.
Han, Yoon-Chi; Kahler, Jennifer; Piché-Nicholas, Nicole; Hu, Wenyue; Thibault, Stephane; Jiang, Fan; Leal, Mauricio; Katragadda, Madan; Maderna, Andreas; Dushin, Russell; Prashad, Nadira; Charati, Manoj B; Clark, Tracey; Tumey, L Nathan; Tan, Xingzhi; Giannakou, Andreas; Rosfjord, Edward; Gerber, Hans-Peter; Tchistiakova, Lioudmila; Loganzo, Frank; O'Donnell, Christopher J; Sapra, Puja.
Afiliación
  • Han YC; Pfizer Inc., Oncology Research & Development, Pearl River, New York. Psapra111@gmail.com yh2029@gmail.com.
  • Kahler J; Pfizer Inc., Oncology Research & Development, Pearl River, New York.
  • Piché-Nicholas N; Pfizer Inc., BioMedicine Design, Cambridge, Massachusetts and Pearl River, New York.
  • Hu W; Pfizer Inc., Drug Safety Research & Development, La Jolla, California.
  • Thibault S; Pfizer Inc., Drug Safety Research & Development, La Jolla, California.
  • Jiang F; Pfizer Inc., Oncology Research & Development, Pearl River, New York.
  • Leal M; Pfizer Inc., BioMedicine Design, Cambridge, Massachusetts and Pearl River, New York.
  • Katragadda M; Pfizer Inc., BioMedicine Design, Cambridge, Massachusetts and Pearl River, New York.
  • Maderna A; Pfizer Inc., Worldwide Medicinal Chemistry, Groton, Connecticut.
  • Dushin R; Pfizer Inc., Worldwide Medicinal Chemistry, Groton, Connecticut.
  • Prashad N; Pfizer Inc., Oncology Research & Development, Pearl River, New York.
  • Charati MB; Pfizer Inc., Oncology Research & Development, Pearl River, New York.
  • Clark T; Pfizer Inc., Procurement, Groton, Connecticut.
  • Tumey LN; Pfizer Inc., Worldwide Medicinal Chemistry, Groton, Connecticut.
  • Tan X; Pfizer Inc., Oncology Research & Development, Pearl River, New York.
  • Giannakou A; Pfizer Inc., Oncology Research & Development, Pearl River, New York.
  • Rosfjord E; Pfizer Inc., Oncology Research & Development, Pearl River, New York.
  • Gerber HP; Pfizer Inc., Oncology Research & Development, Pearl River, New York.
  • Tchistiakova L; Pfizer Inc., BioMedicine Design, Cambridge, Massachusetts and Pearl River, New York.
  • Loganzo F; Pfizer Inc., Oncology Research & Development, Pearl River, New York.
  • O'Donnell CJ; Pfizer Inc., External R&D Innovation, Groton, Connecticut.
  • Sapra P; Pfizer Inc., Oncology Research & Development, Pearl River, New York. Psapra111@gmail.com yh2029@gmail.com.
Clin Cancer Res ; 27(2): 622-631, 2021 01 15.
Article en En | MEDLINE | ID: mdl-33148666
Asunto(s)
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Leucemia Mieloide Aguda / Inmunoconjugados / Subunidad alfa del Receptor de Interleucina-3 / Lectina 3 Similar a Ig de Unión al Ácido Siálico / Gemtuzumab Tipo de estudio: Prognostic_studies Límite: Animals / Humans Idioma: En Revista: Clin Cancer Res Asunto de la revista: NEOPLASIAS Año: 2021 Tipo del documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Leucemia Mieloide Aguda / Inmunoconjugados / Subunidad alfa del Receptor de Interleucina-3 / Lectina 3 Similar a Ig de Unión al Ácido Siálico / Gemtuzumab Tipo de estudio: Prognostic_studies Límite: Animals / Humans Idioma: En Revista: Clin Cancer Res Asunto de la revista: NEOPLASIAS Año: 2021 Tipo del documento: Article